![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The partnership sets out highest ambitions for reaching highest quality and lowest cost levels by introducing Just – Evotec Biologics’ data-driven, fully integrated design capability and continuous manufacturing technology (J.DESIGN) into the field of biosimilars.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Sandoz B2B
Deal Size: $640.0 million Upfront Cash: Undisclosed
Deal Type: Partnership May 09, 2023
Details:
Under the contract, Just – Evotec Biologics will develop mAb-based drug product prototype(s) from sequence discovery or evaluation of existing mAbs to completion of Phase I first-in-human (“FIH”) clinical trials.
Lead Product(s): Monoclonal Antibody
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Department of Defense
Deal Size: $49.9 million Upfront Cash: Undisclosed
Deal Type: Agreement September 20, 2022